Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics

• Prif Awduron: Keyur R. Parmar (Awdur), Pradeep B. Lukka (Awdur), Santosh Wagh (Awdur), Zaid H. Temrikar (Awdur), Jiuyu Liu (Awdur), Richard E. Lee (Awdur), Miriam Braunstein (Awdur), Anthony J. Hickey (Awdur), Gregory T. Robertson (Awdur), Mercedes Gonzalez-Juarrero (Awdur), Andrea Edginton (Awdur), Bernd Meibohm (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: MDPI AG, 2023-06-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Spectinamides 1599 and 1810 are lead spectinamide compounds currently under preclinical development to treat multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. These compounds have previously been tested at various combinations of dose level, dosing frequency, and route of...